The Filing Desk

Evommune vs Pyxis Oncology

Evommune EVMN · Pyxis Oncology PYXS · Pharmaceuticals

Pyxis Oncology reported revenue of $14 million in fiscal 2025, about the same as Evommune's $13 million in fiscal 2025. Evommune's revenue grew 85.7% in its latest year, and Pyxis Oncology's fell 14.2%. Evommune had an operating margin of -623.6%, against -609.2% at Pyxis Oncology. Free cash flow was −$77 million at Evommune and −$64 million at Pyxis Oncology.

Side by side

EvommunePyxis Oncology
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$13M$14M
Revenue growth85.7%−14.2%
Revenue growth a year, last 5 years——
Gross margin—82.8%
Operating margin−623.6%−609.2%
Net margin−529.8%−574.5%
Free cash flow−$77M−$64M
Free cash flow margin−589.8%−458.3%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count306.9%6.3%
Last close$7.24$1.68
P/E at the last close——
Insider trades, last 12 monthsbought $163,610, sold $2.3 millionsold $107,100
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
EvommunePyxis Oncology
Operating margin
Percent of revenue
EvommunePyxis Oncology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
EvommunePyxis Oncology

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Evommune and Pyxis Oncology pages.